Beijing Biostar Pharmaceuticals Co., Ltd. Class H (HK:2563) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Beijing Biostar Pharmaceuticals has entered into a marketing service agreement with Baheal Zhihe, granting them exclusive rights to market and promote Utidelone Injection across mainland China. The agreement, spanning up to 15 years, includes milestone payments tied to research, development, and sales achievements. This strategic move positions Biostar to enhance its market presence and capitalize on Baheal Zhihe’s expertise in medical marketing.
For further insights into HK:2563 stock, check out TipRanks’ Stock Analysis page.